Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 CEO 906 - YUMANITY THERAPEUTICS, INC. | pti-ex321_10.htm |
| EX-31.2 - EX-31.2 CFO - YUMANITY THERAPEUTICS, INC. | pti-ex312_13.htm |
| EX-31.1 - EX-31.1 CEO - YUMANITY THERAPEUTICS, INC. | pti-ex311_9.htm |
| EX-10.28 - EX-10.28 - YUMANITY THERAPEUTICS, INC. | pti-ex1028_418.htm |
| EX-10.27 - EX-10.27 - YUMANITY THERAPEUTICS, INC. | pti-ex1027_419.htm |
| EX-10.26 - EX-10.26 - YUMANITY THERAPEUTICS, INC. | pti-ex1026_318.htm |
| EX-10.25 - EX-10.25 - YUMANITY THERAPEUTICS, INC. | pti-ex1025_320.htm |
| EX-4.6 - EX-4.6 - YUMANITY THERAPEUTICS, INC. | pti-ex46_211.htm |
| 10-K - 10-K - YUMANITY THERAPEUTICS, INC. | pti-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (No. 333-230155, No. 333-223664, No. 333-218544 and No. 333-210521) and Form S-3 (No. 333-228529, No. 333-224180 and No. 333-218545) of Proteostasis Therapeutics, Inc. of our report dated March 10, 2020 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
March 10, 2020